LMR Partners LLP Makes New $7.02 Million Investment in Masimo Co. (NASDAQ:MASI)

LMR Partners LLP purchased a new stake in Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 42,448 shares of the medical equipment provider's stock, valued at approximately $7,017,000. LMR Partners LLP owned 0.08% of Masimo at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Envestnet Asset Management Inc. increased its stake in Masimo by 17.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 31,107 shares of the medical equipment provider's stock valued at $5,142,000 after acquiring an additional 4,579 shares during the period. Lecap Asset Management Ltd. bought a new stake in shares of Masimo in the 4th quarter valued at approximately $1,607,000. Nisa Investment Advisors LLC grew its stake in shares of Masimo by 16,740.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider's stock valued at $835,000 after purchasing an additional 5,022 shares during the period. Trust Point Inc. bought a new position in shares of Masimo during the 4th quarter worth approximately $230,000. Finally, Barclays PLC lifted its position in shares of Masimo by 152.6% during the 3rd quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock worth $5,329,000 after buying an additional 24,137 shares during the period. Institutional investors own 85.96% of the company's stock.

Masimo Price Performance

MASI traded up $1.23 during midday trading on Friday, hitting $155.62. The company had a trading volume of 537,620 shares, compared to its average volume of 659,039. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $194.88. The company has a market capitalization of $8.44 billion, a PE ratio of 107.32 and a beta of 1.23. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm's 50-day simple moving average is $160.28 and its 200-day simple moving average is $167.06.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. The business had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Masimo's revenue for the quarter was down 24.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.77 earnings per share. Equities research analysts predict that Masimo Co. will post 4.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a report on Thursday, April 10th. BTIG Research set a $193.00 price target on shares of Masimo and gave the company a "buy" rating in a research report on Wednesday, May 7th. Wells Fargo & Company dropped their price objective on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating and issued a $200.00 target price (down from $215.00) on shares of Masimo in a report on Wednesday, May 7th. Finally, Raymond James dropped their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Masimo presently has an average rating of "Moderate Buy" and an average price target of $191.60.

Insider Activity at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares of the company's stock, valued at $2,754,601.53. The trade was a 11.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Bilal Muhsin sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $3,946,804.16. The trade was a 29.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,053 shares of company stock worth $6,998,565 over the last 90 days. Insiders own 9.70% of the company's stock.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.